Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Sanofi SA — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.96 (market cap $176.64M), while Sanofi SA trades at $40.22 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 548.1× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Sanofi SA pays a 6.02% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days and Sanofi SA for 94 Days on average.
| RDTE | SNY | |
|---|---|---|
Market Cap | $176.64M | $96.81B |
Volume | 116,818 | 2,081,815 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $52.34 |
52-Week Low | $25.96 | $39.51 |
Typical Hold Time | 53 Days | 94 Days |
Enterprise Value | — | $116.20B |
Dividend Yield | — | 6.02% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →